(AOF) – Sanofi and Teva Pharmaceuticals, American subsidiary of Teva Pharmaceutical Industries Ltd. have entered into a collaboration for the co-development and co-commercialization of TEV’574, an asset currently undergoing phase IIb clinical trials for the treatment of ulcerative colitis and Crohn’s disease, two diseases intestinal inflammation. This collaboration is part of the French pharmaceutical group’s strategy in immunology, which consists of studying innovative mechanisms of action for the treatment of chronic inflammatory diseases.
Under the terms of this new collaboration agreement, Teva will receive an upfront payment of 469 million euros ($500 million) and up to 940 million euros ($1 billion) in milestone payments, depending on the achievement of development and marketing objectives.
The two companies will share global development expenses, as well as net profits and losses in major markets. In other markets, royalty agreements will be put in place.
Sanofi will lead development activities applicable to the Phase III program. Teva will be responsible for marketing the product in Europe, Israel and certain other countries. Sanofi will lead commercialization activities in the United States, Japan, other Asian countries and the rest of the world.
The proposed transaction will take effect once customary closing conditions have been satisfied. The first results of the program should be available in 2024.
Paul Hudson, Chief Executive Officer of Sanofi, said “Anti-TL1A represents a promising pharmacotherapeutic class and we believe TEV’574 could become a best-in-class option for the treatment of serious gastrointestinal diseases.”
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
